Impact of rapid treatment for pediatric status epilepticus (VIDEO)

Article

For Contemporary Pediatrics, Dr Bobby Lazzara discusses a multicenter observational study published in JAMA Neurology that looked at time to treatment in children with refractory convulsive status epilepticus and the impact on mortality.

For Contemporary Pediatrics, Dr Bobby Lazzara discusses a multicenter observational study published in JAMA Neurology that looked at time to treatment in children with refractory convulsive status epilepticus and the impact on mortality.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital | Image credit: Boston Children's
Michael, Kruer, MD
Michael Kruer, MD
H. Westley Phillips, MD
H. Westley Phillips, MD
Alan Percy, MD
Alan Percy, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Related Content
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Michael O. Daines, MD
June 19th 2025
Article

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

Site Logo

PODCAST: Auditory brain stem implants in young children.

January 14th 2016
Podcast

Jamie Glater, MD, discusses an NIH-sponsored study investigating the effectiveness of an auditory brain stem implant in young children with congenital cochlear nerve agenesis.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Joshua Fitch, Senior Editor
June 18th 2025
Article

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

Full recap from the 2025 Pediatric Academic Societies meeting | Image Credit: © SCStock - © SCStock - stock.adobe.com.

Full recap from the 2025 Pediatric Academic Societies meeting

Joshua Fitch, Senior Editor
May 1st 2025
Article

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

Youth with neurodevelopmental disabilities face higher risk of poor cardiovascular health | Image Credit: © adobedesigner - stock.adobe.com.

Youth with neurodevelopmental disabilities face higher risk of poor cardiovascular health

Morgan Ebert, Managing Editor
April 26th 2025
Article

New data from national survey highlights disparities and need for focused prevention strategies.

Pegtarazimod data confirms inflammation biomarkers in hypoxic ischemic encephalopathy infants | Image Credit: © Carl - © Carl - stock.adobe.com.

Pegtarazimod data confirms inflammation biomarkers in hypoxic ischemic encephalopathy infants

Joshua Fitch, Senior Editor
April 25th 2025
Article

In addition, data presented at PAS revealed a predictable pharmacokinetic profile in the newborn population, consistent with adult humans.

© 2025 MJH Life Sciences

All rights reserved.